Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst

Alnylam has offered a closer look at the data that could support Onpattro’s quest to expand into a rare heart disease. While an approval looks likely, some industry watchers have raised fresh doubts about the drug’s commercial opportunity in its potential fight against Pfizer.